

Everest Medicines signs new deal targeting drug resistance

14 January 2019 | News

Spero Therapeutics has signed license agreement with Everest Medicines to develop, manufacture and commercialize SPR206 in Asia.



Spero Therapeutics, Inc., a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant (MDR) bacterial infections, and Everest Medicines have announced that they have entered into a collaboration to develop, manufacture and commercialize SPR206 in Greater China, South Korea and certain Southeast Asian countries, along with an exclusive option to rights to SPR741 in the Territory.

SPR206 and SPR741, two intravenous (IV)-administered product candidates from Spero's Potentiator Platform, are being developed as innovative options to treat MDR Gram-negative bacterial infections.

Spero will receive an upfront payment of \$2 million and is eligible to receive milestone payments of up to an additional \$59.5 million upon achievement of specified clinical, regulatory and commercial milestones related to SPR206, of which Spero anticipates receiving at least \$2 million in near-term milestones during 2019.